G promoting effects on the body. GH has also been implicated in immune development and function.' There is also evidence, primarily through in vitro analysis, that G H can influence hematopoie~is.2,~ GH has been shown to directly enhance erythropoiesis in vitro: and GH-deficient dwarf mice have been reported to exhibit suppressed splenic hematopoietic progenitor cell content.4 Additionally, GH has been shown to indirectly stimulate granulopoiesis in vitro through the release of secondary mediators such as insulin-like growth factor-1 (IGF-l). 3 Azidothymidine (AZT) is a reverse transcriptase inhibitor currently used as a treatment for acquired immune deficiency syndrome (AIDS). One of the significant doselimiting toxicities of AZT involves an anemia and neutropenia arising from its myelotoxic effects on the m a r r o~.~ We examined whether recombinant human GH (rhGH) would be an effective hematopoietic stimulating agent when administered in vivo and whether it would counteract the myelosuppressive properties of AZT. We report here that human GH exerts significant hematopoietic growth-promoting effects in vivo, partially reverses the myelosuppression by AZT, and may be of use clinically to promote hematopoiesis in the face of AZT or other myelotoxic therapy.
MATERIALS AND METHODS
Mice. C57BLI6 (B6), BALBIc, and CB17 scidlscid (SCID) mice were obtained from the Animal Production Facility (NCI-FCRDC, Frederick, MD) and were not used until 8 weeks of age. SCID mice were housed under specific pathogen-free conditions at all times.
Blood was collected from mice via the lateral tail vein, using EDTA as an anticoagulant. Complete blood counts were performed with a Coulter counter (Coulter, Hialeah, FL) and differential cell counts were performed by microscopic examination of Wright's stained peripheral blood smears (MetPath, Inc, Rockville, MD). Samples were run through a Coulter STKS (Coulter) and a manual differential count was performed.
Statistics were performed comparing different values using parametric analysis with the Student's t-test. All experiments had at least three mice per group and were performed at least three times.
Hematopoietic analysis.
every other day) was concurrently administered with AZT. Administration of ovine GH (ovGH), which, unlike rhGH, has no effect on murine prolactin receptors, also prevented the erythroid-suppressive effects of A73 in mice, but had no significant effect on granulocyte counts. Thus, the effects of GH are mediated at least in part through GH receptors in vivo. Additionally, when mice were initially myelosuppressed by several weeks of AZT treatment, the subsequent administration of ovGH resulted in an increase in splenic hematopoietic progenitor cells. No significant pathologic effects were observed in mice receiving either repeated rhGH or ovGH injections. Thus, GH exerts significant direct hematopoietic growth-promoting effects in vivo and may be of potential clinical use to promote hematopoiesis in the face of myelotoxic therapy. This is a US government work. There are no restrictions on its use.
Assay for in vitro hematopoiesis. Spleen cells (SC) or bone marrow cells (BMC) from mice were washed and resuspended in Iscove's modified Dulbecco's medium with 10% fetal bovine serum, 1% L-glutamine, and antibiotics (complete Iscove's modified Dulbecco's medium). Nucleated cells were counted on a Coulter counter (Coulter). The cells were then plated in 0.3% bactoagar (Difco Laboratories, Detroit, MI) in 35-mm Lux petri dishes (Miles Laboratories, Inc, Naperville, IL) at a concentration of 1 x 105 BMC or 5 x lo5 spleen cells per plate. Colony formation was stimulated in some instances with predetermined optimal doses of growth-promoting cytokines such as recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF) at 10 ng/mL (Amgen Corporation, Thousand Oaks, CA) and purified murine interleukin-3 (IL-3; 10 ng/mL) supplied by the Biological Response Modifiers Program Repository (Frederick, MD). Plates were incubated at 37°C for 7 days in 100% humidity, 5% CO2 atmosphere. All experiments had at least three mice per group and were performed two to four times, with a representative experiment being shown. A Student's t-test was performed to determine if the values differed significantly (P < .001). 
Treatment with AZT.

RESULTS
Administration of rhGH in vivo results in an increase in hematopoieticprogenitor cells. To determine if rhGH could exert hematopoietic growth promoting properties in vivo, BALB/c mice and mice with severe combined immune deficiency (SCID) were administered injections of 20 pg of rhGH every other day for 7 days (a total of three injections). A soft agar colony assay was then performed to determine hematopoietic progenitor cell content of BMC and SC. SCID mice were used because they lack T cells and B cells due to an inability to productively rearrange their immune receptor genes6 These mice allowed us to determine if the hematopoietic effects of rhGH were due to the production of cytokines by T cells because GH has been shown to stimulate T cells. ' The results showed that the administration of rhGH resulted in significant (P < .001) increases in splenic and BMC colony-forming unit granulocyte-macrophage (CFU-GM) colonies in both BALB/c and SCID recipients (Table 1) . Splenic cellularity was also increased after rhGH treatment (Table 2) . However, no significant effects were detected on BMC cellularity or on peripheral blood differential counts in the normal recipients, even when 100-pg doses of rhGH were administered (data not shown). Additionally, no significant increases in body weight were noted in the recipients receiving 20-pg injections of rhGH (data not shown). Therefore, rhGH appears to exert significant hematopoietic growth-promoting effects after in vivo administration. Because rhGH treatment also increased the splenic hematopoietic progenitor cell content in SCID mice, these results also suggest that rhGH is not exerting its hematopoietic effects indirectly by inducing colony-stimulating factor production by T cells.
rhGH treatment prevents the myelosuppressive properlies of AZT. Because one of the dose-limiting toxicities of AZT is anemia and neutropenia resulting from its myelotoxic properties, we then examined whether concurrent treatment of mice with rhGH and AZT would result in an improvement in their hematologic parameters. B6 mice were placed on AZT (1 mg/mL in drinking water) for several weeks. Upon analysis, these mice exhibited significantly lower (P < .001) BMC cellularity (Table 3) , splenic hematopoietic progenitor cell content (Table 4) , hematocrit (HCT) (Fig l) , and white blood cell (WBC) counts (Fig 2) than control mice. These effects became more pronounced the longer the mice were placed on AZT, with most hematologic values approaching half the control values. If mice were concurrently treated with 20-pg injections of rhGH administered every other day, all of these hematologic parameters improved significantly (P c: .001).
The absolute number of segmented cells also increased in response to rhGH treatment, increasing from 445 4 85/ mm3 to 840 ? 26/mm3 with mice placed on AZT and examined at day 21 after concurrent rhGH treatment. Similar results were obtained after 28 days (absolute granulocyte count was 889 f l10/mm3 on AZT alone compared with 1,485 2 33/mm3 in mice on AZT plus GH). However, the hematologic parameters failed to attain control values, even when higher doses (100 pg) of rhGH For were administered (data not shown). Additionally, the mice exhibited no apparent pathologic effects from repeated rhGH administration. The mice appeared to be in good health throughout the study. They maintained a constant weight and mice killed at the end of the study showed no gross pathologic abnormality. Thus, treatment of mice with rhGH partially ameliorates the anemia and neutropenia arising from AZT treatment.
ovGH prevents and reverses the myelosuppression induced
by AZT treatment. Because hGH has been reported to be capable of binding the prolactin receptor: it is possible that rhGH can mediate its hematopoietic effects via the prolactin receptor pathway. To address this question, mice were treated with 20-pg injections of ovGH every other day to determine if ovGH would also counteract the myelosuppression caused by AZT treatment. ovGH does not bind to the murine prolactin receptor and any hematopoietic effects it exerts would be due to binding the GH receptor.' The results show that administration of ovGH can also counteract the myelosuppressive effects of AZT as determined by HCT (Fig 3) and splenic hematopoietic progenitor cell content (Table 5 , experiment A). However, no significant increases in WBC counts were obtained after ovGH treatment (data not shown).
Later ovGH treatment partially reverses the myelosuppression induced by AZT. It was then of interest to determine if the administration of ovGH after myelosuppression was already induced by AZT would improve hematologic parameters. Mice were administered AZT and after 3 weeks were analyzed to confirm that they were myelosuppressed. They then received 20-pg injections of ovGH administered every other day for 7 and 14 days. Upon analysis of both time points, significant improvement of splenic hematopoietic progenitor cell content was noted in the ovGH-treated For recipients (Table 5 , experiment B), indicating that later ovGH administration also results in the partial reversal of myelosuppression induced by AZT. Similar results were obtained with rhGH (data not shown).
DISCUSSION
GH has a variety of biologic effects in vivo and has been suggested to exert effects on immune system development. ' We report here that rhGH also enhances hematopoiesis when administered in vivo and can prevent or reverse the myelosuppression induced by AZT. Both the anemia and neutropenia resulting from AZT treatment were improved by the administration of rhGH. It is important to note that the hematopoietic growth-promoting effects of GH administration occurred at a dose regimen that did not result in significant body weight gain. Thus, the doses required for the manifestation of the hematopoietic effects of GH are not so high that undesirable side effects (such as growth) or significant pathology were noted.
The hematopoietic effects of rhGH could be due to both direct and indirect mechanisms. The data using SCID mice show that rhGH does not require T cells to produce its hematopoietic effects. While GH has been shown to exert hematopoietic growth-promoting effects in v i t r~,~,~ little is known about its effects in vivo. It has been shown that GH can directly enhance erythropoiesis in vitro2 and these properties may explain the increase in HCT levels in mice treated with both AZT and GH. Additionally, many of the growth-promoting effects of GH are mediated by IGF-I, which is produced in the liver in response to GH.8 GH has also been shown to enhance granulopoiesis in vitro through the induction of IGF-I release by adherent cells in the BM.3 Furthermore, BM stromal cells have been recently reported to secrete IGF-1.9 Because the data presented here show that rhGH administration to mice placed on AZT resulted in the improvement of both WBC counts and HCTs, part of the hematopoietic effects of GH administration may be due to the induction of IGF-I release. However, the lack of effect of ovGH on WBC counts suggests that rhGH may mediate some of its granulopoietic effects via its ability to stimulate prolactin receptor^.^ We have found that dwarf mice, which lack GH and other neuroendocrine mediators, such as IGF-I and prolactin$ also display suppressed hematologic parameters, and treatment of the mice with rhGH resulted in an improvement of hematologic parameters involving both myeloid and erythroid lineages.1° Preliminary results also indicate that treatment of mice with IGF-I produces significant hematopoietic growth-promoting effects (manuscript in preparation).
Human GH has also been shown to be capable of binding the prolactin r e~e p t o r ,~ and some of the in vivo effects of rhGH may be due to this binding capability. Indeed, we have preliminary results indicating that prolactin exerts significant hematopoietic growth-promoting properties when administered in vivo and can also counteract the myelosuppression caused by AZT treatment (manuscript in preparation). However, the data obtained using ovGH, which does not bind the murine prolactin receptor: indicate that at least some of the hematopoietic effects of rhGH are due to GH receptor binding activity because ovGH administration also yielded significant hematopoietic growth-promoting effects, particularly in the erythroid series.
The minimal toxicities associated with rhGH administration make it an attractive therapeutic agent in patients with AIDS undergoing AZT therapy." In contrast, many cytokines (GM-CSF and IL-1) currently used to augment hematopoiesis clinically have significant dose-limiting toxicitiesI2 or affect only the neutropenia resulting from AZT treatment. 13 The use of rhGH resulted in increases in both erythroid-and myeloid-lineage cells and this may be more efficacious, less toxic, and less expensive than administering various myeloid-lineage-specific cytokines with or without erythropoietin or transfusions. Whereas rhGH has been shown to increase viral replication in human immunodeficiency virus (H1V)-infected T cells in vitro, coculture with AZT abolished this activity, suggesting that rhGH does not interfere with A Z T ' s reverse transcriptase-inhibiting funct i o n~. '~ Because GH has also been suggested to improve T-cell function' and can result in increased body mass in patients with AIDS,15 the use of rhGH in AIDS may offer other benefits in addition to the hematopoietic growthpromoting effects it may exert. HIV-infected individuals have also been shown to have defects in neutrophil respiratory burst and defects in the microbicidal capability of their neutrophils and monocytes.16 GH has been recently shown to prime neutrophils for superoxide anion secretion" and has also been shown to exert similar effects on macrophages.18 This suggests that rhGH may be of significant therapeutic use in AIDS for a variety of hematologic and immunologic reasons. However, while these results suggest that GH administration can improve hematologic parameFor personal use only. on October 25, 2017. by guest www.bloodjournal.org From ters after AZT treatment, it must be acknowledged that not all the peripheral cytopenias seen in AIDS patients are related to AZT toxicity alone. HIV infection may also impair hematopoiesis. Because rhGH does not appear to exert antiviral effects, it may have no effect on retroviralmediated suppression of hematopoiesis in HIV infection. More work needs to be performed concerning the effects of GH in situations where both AZT treatment and active HIV infection occurs.
The use of rhGH may also improve hematopoietic engraftment after BM transplantation (BMT) or improve hematologic parameters in patients undergoing chemotherapy or radiation therapy. Preliminary results indicate both GH and prolactin administration resulted in greater hematopoietic engraftment in mice after syngeneic BMT (manuscript in preparation). Thus, rhGH exerts significant hematopoietic effects in vivo and may be of considerable clinical use to augment hematopoiesis in humans.
